Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.69 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497642 | 1.00 | PTPN1 (0.69) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 | |
| SCHEMBL4756917 | 0.83 | ERN1 (0.50) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 | |
| SCHEMBL373244 | 0.81 | ERN1 (0.52) | PTPN1PTPN6PTPN2TTRERN1 | |
| SCHEMBL5463920 | 0.80 | PTPN1 (0.50) | PTPN1PTPN6PTPN2PIM1 | |
| SCHEMBL7767550 | 0.79 | PTPN1 (0.45) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 | |
| SCHEMBL2511971 | 0.79 | PTPN1 (0.45) | PTPN1PTPN6PTPN2ERN1 | |
| SCHEMBL10763255 | 0.77 | PTPN1 (0.46) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 | |
| SCHEMBL1984171 | 0.77 | HMGB1 (0.55) | PTPN1PTPN6PTPN2TTR | |
| SCHEMBL5777093 | 0.77 | APP (0.45) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 | |
| SCHEMBL330545 | 0.75 | AKR1C3 (1.00) | PTPN1PTPN6PTPN2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879661-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-01-23 | — | — | EP | claimed |
| WO-2006119821-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| CN-119462555-A | Sulfonamide compound and application thereof | 上海科技大学 | 2025-02-18 | — | — | CN | disclosed |
| US-10980890-B2 | Compounds comprising self-immolative group | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-04-20 | — | — | US | disclosed |
| CN-107648613-B | Compounds comprising self-immolative groups | 乐高化学生物科学股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200069816-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2020-03-05 | — | — | US | disclosed |
| US-10383949-B2 | Compounds comprising self-immolative group | LEGOCHEM BIOSCIENCES, INC. (KR) | 2019-08-20 | — | — | US | disclosed |
| US-10183997-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2019-01-22 | — | — | US | disclosed |
| US-20180353611-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2018-12-13 | — | — | US | disclosed |
| US-10118965-B2 | Compositions and methods related to anti-EGFR antibody drug conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-11-06 | — | — | US | disclosed |
| US-9993568-B2 | Compounds comprising self-immolative group | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-06-12 | — | — | US | disclosed |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| WO-2017051249-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| WO-2017051249-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051254-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | WO | disclosed |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2016-06-30 | — | — | US | disclosed |
| WO-2015182984-A1 | COMPOUND CONTAINING SELF-IMMOLATIVE GROUP | 주식회사 레고켐 바이오사이언스 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183997-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | CD47, CD22, BCL6 | PTPN1 447/4885PTPN6 400/4885PTPN2 461/4885 |
| US-20200069816-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | PTPN1 1207/4885PTPN6 1052/4885PTPN2 1062/4885 |
| US-10383949-B2 | Compounds comprising self-immolative group | IAPP, IDE, DNPEP | PTPN1 1255/4885PTPN6 1057/4885PTPN2 1133/4885 |
| US-20180353611-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | PTPN1 1255/4885PTPN6 1057/4885PTPN2 1133/4885 |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PTPN1 336/4885PTPN6 240/4885PTPN2 375/4885 |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | PTPN1 1255/4885PTPN6 1057/4885PTPN2 1133/4885 |
| US-10980890-B2 | Compounds comprising self-immolative group | IAPP, IDE, DNPEP | PTPN1 1207/4885PTPN6 1052/4885PTPN2 1062/4885 |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD47, CD22, BCL6 | PTPN1 447/4885PTPN6 400/4885PTPN2 461/4885 |
| US-10118965-B2 | Compositions and methods related to anti-EGFR antibody drug conjugates | EGFR, ERBB2, ERBB3 | PTPN1 336/4885PTPN6 240/4885PTPN2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.